Molecular Biometrics Inc. is touting new data showing the effectiveness of its ViaMetrics-E metabolomic test in assessing the viability of human embryos for in vitro fertilization. Typically, doctors use a visual, morphology examination of embryos to assess their viability.
Molecular Biometrics Inc.
Jim Posillico has a long academic and commercial pedigree in reproductive medicine, having spent time as a researcher at Harvard Medical School, Serono Laboratories, the Ares-Serono Group, InterMune Life Sciences and SAGE BioPharma.
So when he learned of a metabolomics platform being developed at McGill University, he was quick to realize its applicability to a variety of potential conditions and disease states. The technology allows the comparison of biomarkers produced by cell metabolism monitor the progress of diseases like Parkinson’s and Alzheimer’s.
Molecular Biometrics Inc. pulled in $12.5 million in Series B financing, led by new investor Atlas Venture.
The Norwood, Mass.-based firm is working on a diagnostic to determine the most viable embryos for use in in vitro fertilization procedures, with an eye toward reducing the risk of multiple births and improving IVF pregnancy rates.